Individualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes: Practical lessons from ACCORD and other cardiovascular trials

• Autores: Matthew C Riddle, Diane M. Karl
• Localización: Diabetes care, ISSN-e 0149-5992, Vol. 35, Nº. 10, 2012, págs. 2100-2107
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Two other meta-analyses, which added additional randomized studies to the large trials, concluded that available data show limited and inconclusive evidence of risk reduction for CV end points but confirmed a substantial increase of severe hypoglycemia (11,12). The persistent effect of early treatment also suggests that prior poor metabolic control may result in anatomic changes that are not easily reversed. [...]late-stage, high-risk patients of the kind selected for ADVANCE, ACCORD, and VADT may be less likely to benefit from glycémie control after years of hyperglycemia.